. However, the exact conditions required for the development of antigen (Ag)-specific T regs from PSCs (i.e., PSC-T regs ) are not well delineated. Ag-specific PSC-T regs can be tissue/ organ-associated and migrate to local inflamed tissues/organs to suppress the autoimmune response after adoptive transfer, thereby avoiding potential overall immunosuppression from non-specific T regs . In this study, we developed a new approach to generate functional Ag-specific T regs from induced PSCs (iPSCs), i.e., iPSC-T regs , which had the ability to generate an Ag-specific immunosuppressive response in a murine model of arthritis. We retrovirally transduced murine iPSCs with a construct containing genes of Ag-specific T cell receptor (TCR) and the transcriptional factor FoxP3. We differentiated the iPSCs into Ag-specific iPSC-T regs using in vitro or in vivo Notch signaling, and demonstrated that adoptive transfer of such T regs dramatically suppressed autoimmunity in a well-established Ag-induced arthritis model, including the inflammation, joint destruction, cartilage prostaglandin depletion, osteoclast activity, and Th17 production. Our results indicate that PSCs can be used to develop Ag-specific T regs , which have a therapeutic potential for T reg -based therapies of autoimmune disorders.
Regulatory T cells (T regs ) are a component of the normal immune system and contribute to the maintenance of peripheral tolerance. T regs are a subset of specialized CD4 + helper T (Th) cells defined phenotypically by the expression of the IL-2 receptor α -chain (CD25) and the transcription factor FoxP3, which is required for T reg development and controls a genetic program specifying this cell fate. T regs can down-regulate immune responses and are essential for immune homeostasis 1 . T regs are key effectors in preventing and treating autoimmune disorders, e.g., rheumatoid arthritis (RA), type-1 diabetes (T1D), and inflammatory bowel diseases (IBD), and controlling both transplant rejection and graft-versus-host disease (GVHD) [2] [3] [4] [5] . T reg -based immunotherapy is a highly promising treatment for a variety of autoimmune disorders, and facilitation for organ transplantation 2 . Although a precise understanding of the immunosuppressive mechanism of T regs remains indefinable, there is increasing evidence that T regs manifest their function through a myriad of mechanisms that include the secretion of immunosuppressive soluble factors (e.g., TGF-β , IL-10, and IL-35), cell contact mediated regulation via the high affinity TCR and other membrane-bound molecules (e.g., CTLA-4, GITR, LAG-3), and cytolytic activity. Recent advances in the use of large-scale in vitro expansion of T regs followed by in vivo re-infusion of these cells raise the possibility that this strategy may be successfully utilized for the treatment of autoimmune disorders 6, 7 . Although polyclonally expanded populations of T regs exhibit suppressive activity, Ag-specific T regs appear superior in suppressing local autoimmune disorders such as RA, autoimmune diabetes and GVHD [8] [9] [10] [11] [12] . In addition, tissue/organ (e.g., joints, pancreas, intestine)-associated targeting of T regs stables FoxP3 expression and avoids induction of a potentially detrimental systemic immunosuppression 13, 14 . For T reg -based immunotherapy, the in vitro generation of tissue/organ-associated and non-terminally differentiated effector T regs for in vivo re-infusion is an optimal approach. However, current methodologies are limited in terms of the capacity to generate, isolate, and expand a sufficient quantity of such T regs from patients for therapeutic interventions.
Under the right circumstance, PSCs can produce almost all of the cells in the body, including T regs . PSCs provide a chance to obtain a renewable source of healthy T regs to treat a wide array of autoimmune disorders. However, the right circumstances for the development of antigen (Ag)-specific T regs from PSCs (i.e., PSC-T regs ) has not been fully defined, especially the signaling mechanisms that direct differentiation of such PSC-T regs . Previous studies have shown the successful T cell development from PSCs (5, 6) , and we have shown T lineage differentiation from iPSCs (7) . However, it remains unclear whether iPSCs can differentiate into functional Ag-specific T regs for T reg -based immunotherapy.
In this study, we developed a new approach to generate Ag-specific T regs from iPSCs, i.e., iPSC-T regs , which have the ability to suppress autoimmunity in a murine model of arthritis. We retrovirally transduced murine iPSCs with a DsRed reporter construct containing genes of major histocompatibility complex (MHC) II (I-A b )-restricted ovalbumin (OVA)-specific TCR and the transcriptional factor FoxP3. We differentiated the DsRed + iPSCs into OVA-specific iPSC-T regs with an OP9 stromal cell line expressing Notch ligands DL1, DL4 and I-A b in the presence of recombinant cytokines of rIL-7 and rFlt3L. We visualized the expression of CD3, TCR, CD4, CD25, and CTLA4 on OVA-specific iPSC-T regs . Adoptive transfer of such T regs dramatically suppressed autoimmunity in a well-established Ag-induced arthritis (AIA) model, including the inflammation, joint destruction, cartilage proteoglycan depletion, and osteoclast activity. In addition, we measured the IL-17 cytokine secretion from the lymph nodes draining into the joints. We found that FoxP3 and TCR-transduced T regs reduced the number of Th17 producing cells in the OVA-injected knees, where inflammation, bone destruction, cartilage depletion, and osteoclast-like activity were also reduced. Our results indicate that iPSC-derived Ag-specific T regs have a great potential to be used for the treatment of autoimmune disorders.
Results
Generation of Ag-specific iPSC-T regs . Previously we have shown that iPSCs have the ability to differentiate into T regs 15 , so we sought to investigate whether iPSCs can be induced to differentiate into Ag-specific T regs . We used the MiDR retrovirus-mediated transduction and transduced mouse iPSCs with MHC II (I-A b )-restricted OVA 323-339 -specific TCR and FoxP3 (MiDR-TCR-FoxP3, Fig. 1A ), followed by a co-culture with OP9 stromal cells expressing Notch ligands DL1, DL4 and I-A b (OP9-DL1/DL4/I-A b ) in the presence of recombinant cytokines of rIL-7 and rFlt3L. Upon gene transduction, we visualized the DsRed expression by fluorescence microscopy (Fig. 1B) , and sorted GFP + DsRed + cells (Fig. 1C) . We confirmed FoxP3 expression in the sorted cells by Flow cytometry and Western blotting (Fig. 1D) . To determine whether the TCR and FoxP3 gene-transduced iPSCs were capable of undergoing the differentiation of Ag-specific T regs , we first analyzed the iPSC morphological growth in the presence of Notch signaling. After 7 days of culture with the OP9-DL1/DL4/I-A b cells, iPSCs differentiated into mesoderm-like cells, and were associated with non-adherent grape-like clusterson on day 14. On day 22, lymphocyte-like cells spread fully in the plate (Fig. 1E) . We further analyzed the cell surface markers of the iPSC-derived cells. On day 28 of in vitro co-culture, the iPSC-derived cells substantially expressed CD3 and Ag-specific TCR, two T cell markers. The CD3 + TCRVβ 5 + population expressed CD4. Most of the CD3
+

TCRVβ 5
+ CD4 + cells also expressed CD25, CD127, and CTLA-4, which are typically expressed at elevated levels in naturally occurring T regs (nT regs ) (23, 24, 25) and in T cells expressing FoxP3 ectopically (26, 27) . We also determined that FoxP3 expression in the iPSC-derived cells persisted even after long-term in vitro stimulation with the Notch ligand as detected by intracellular staining analyzed by flow cytometry (Fig. 1F) . Collectively, our results suggest that iPSCs have the ability to differentiate into Ag-specific CD4 + CD25 + FoxP3 + T regs by the approach of gene transduction of Ag-specific TCR and FoxP3, followed by stimulation with Notch signaling.
Functional analyses of Ag-specific iPSC-T regs .
To determine the functional status of Ag-specific iPSC-T regs , we tested whether these iPSC-T regs had the capacity to produce the suppressive cytokines of IL-10 and TGF-β , following Ag stimulation. On day 28 of in vitro co-culture, we isolated the CD4 +
CD8
-single-positive (SP) iPSC-T regs and stimulated with T-depleted splenocytes pulsed with OVA 323-339 peptide, and assessed cytokine production. The iPSC-T regs produced LAP (TGF-β) and IL-10 but not IL-2 and IFN-γ as detected by surface or intracellular staining ( Fig. 2A,B) , indicating that the iPSC-T regs are anergic and have potential suppressive activities.
To further show the functional activity of Ag-specific iPSC-T regs , we performed an in vitro suppressive assay. We mixed OVA-specific iPSC-T regs on day 28 of the in vitro co-culture or nT regs from OT-II TCR Tg mice with naive CD4 + CD25 − T cells (target cells) from C57BL/6 mice (T regs /Target cells = 1:10) and stimulated with T-depleted splenocytes pulsed with OVA 323-339 peptide (T/APCs = 1:4) for 2 days. Supernatants from target cells stimulated with iPSC-T regs or nT regs showed a substantial decrease in the amounts of IL-2 and IFN-γ , as compared to those from target cells alone (Fig. 2C) . In a separate set of experiments, effector cells significantly suppressed the proliferation of target cells after OVA peptide stimulation (Fig. 2D) . Taken together, these results show that in vitro-derived Ag-specific iPSC-T regs are functionally mature.
In vivo programming of Ag-specific iPSC-T regs . Our previous study showed that TCR gene-transduced iPSCs developed into Ag-specific T cells in vivo 16 . We tested whether the OVA TCR and FoxP3 gene-transduced iPSCs have the ability to differentiate into OVA-specific T regs in vivo. We co-cultured the OVA TCR and FoxP3 gene-transduced iPSCs (Thy 1.2 + ) on the OP9-DL1/DL4/I-A b cells for 7 days, and then adoptively transferred the iPSC-derived cells into the recipient congenic mice (Thy 1.1 + ). We i.p. injected agonistic α -Notch2 Ab 17, 18 and recombinant cytokines (e.g., rIL-7, rFlt3L) twice a week to boost the development of OVA-specific iPSC-T regs in vivo. (Fig. 3a) , which expressed CD25 and FoxP3 (Fig. 3b) signaling promotes the development of Ag-specific iPSC-T regs . Thy1.2 + TCRVβ 5 + cells from the pooled lymph nodes and spleen were able to respond to Ag stimulation and produced IL-10 and TGF-β (Fig. 3c ). These results demonstrate the development of Ag-specific iPSC-T regs using in vivo Notch signaling.
Ag-specific iPSC-T regs ameliorate Ag-induced arthritis (AIA).
Therapies that restore or supplement T reg function and number have the ability to inhibit the onset and progression of a number of autoimmune disorders [19] [20] [21] [22] [23] . To characterize the functional activity of Ag-specific iPSC-T regs in physiological settings, we used the animal protocol wherein murine arthritis was induced in C57BL/6 mice by AIA. In the AIA model, we immunized mice with methylated BSA (mBSA) followed by intra articular knee re-challenge with mBSA to induce T-cell mediated tissue damage 9 . We co-cultured the OT-II TCR and FoxP3 gene-transduced iPSCs on the OP9-DL1/DL4/I-A b cells for 7 days, and then adoptively transferred iPSC-derived cells into the recipient mice that were induced AIA two weeks later after the cell transfer. In the first set of experiments, we tested whether the transferred cells were able to home to the appropriate site, suppress in an Ag-specific fashion, and consequently control joint inflammation locally. We challenged each animal in one knee (right) with mBSA and OVA, and in the contralateral control knee (left) with mBSA alone. As a result, only one knee contained the OVA Ag recognized by the Ag-specific T regs , while both knees contained the mBSA Ag recognized by the arthritis-inducing T cells. The results showed that the transferred iPSC-derived cells substantially decreased the inflammatory knee swelling when OVA was present, but had no effect on the control knee that was injected with mBSA only (Fig. 4) . In a control group, FoxP3-transduced T cells also reduced inflammation, but had a lower level than the On day 7, the gene-transduced cells (3 × 10 6 /mouse) were adoptively transferred into female C57BL/6 mice that were induced AIA two weeks later after the cell transfer. On the following day of arthritis induction, the arthritis severity was monitored by measurement of the knee diameter. (A-C) % increase in knee diameter. Increase in knee diameter was calculated based on preinjection knee diameter for each mouse before injection on day 0. Arthritis score was evaluated by examining the both knees by a blinded manner and each knee was assigned a score, as follows: 0, no visible swelling or discoloration; 1, visible swelling with or without discoloration; 2, moderate swelling with discoloration; 3, severe swelling with discoloration. In each group five mice were used and data are representative of three independent experiments. Data are represented as the mean ± SD. (D) The mean scoring on day 7 for both knees from five mice. Data are represented as the mean ± SD from three independent experiments (**p < 0.01, ***p < 0.001, two-way ANOVA).
transduced iPSC-derived cells. On day 7, after AIA, we sacrificed mice and removed both knees for histopathological examination to detect in vivo tissue damage. Using the Safranin O staining, we observed in the vector control (MiDR) group, there was a loss of cartilage and joint destruction over large areas of the joint surface of both bones. In the MiDR-FoxP3 group 15 , there was a loss of cartilage, but mainly restricted to one bone surface of the joint. In the MiDR-TCR-FoxP3 group, there was no obvious loss of cartilage, showing normal knee architecture with an area of limited cartilage thinning (Fig. 5A,C) . Using the HE staining, we identified that compared with the MiDR group in which the right knees showed considerable cellular infiltration over a large proportion of the joint surface, the MiDR-FoxP3 or MiDR-TCR-FoxP3 group had few cellular infiltration areas (Fig. 5B,C) . These results showed that lymphocyte infiltration and bone erosion were markedly reduced in the right knees where OVA was present. In the second set of experiments, we investigated whether Ag-specific iPSC-T regs could suppress cartilage depletion and prevent osteoclast-like activity. In autoimmune arthritis, bone destruction is attributable to excessive bone resorption by osteoclasts, the formation of which is directly and indirectly regulated by CD4 + T cells infiltrating into the lesion (29, 30) . Osteoclasts are multinucleated cells of monocyte/macrophage lineage that degrade bone matrix and dynamically remodel the skeleton (31) (32) (33) . During autoimmune arthritis, cartilage proteoglycan depletion and osteoclast activity are markedly increases. In the AIA model, we identified the increased cartilage proteoglycan depletion and osteoclast-like activity, which was correlated with the increase of joint inflammation and bone erosion. On day 7, after the AIA, we sacrificed mice and removed both knees for histopathological examination to detect osteoclast-like activity and proteoglycan depletion. Using Safranin O staining, we observed in the vector control (MiDR) group, there was severe cartilage proteoglycan depletion, which was reduced or dramatically reduced in the MiDR-FoxP3 or MiDR-TCR-FoxP3 group, separately (Fig. 5D) . Using Cathepsin K staining, we identified that compared with the MiDR group in which the right knees showed a number of cellular infiltration areas with multinucleated osteoclasts, the MiDR-FoxP3 or MiDR-TCR-FoxP3 group had reduced or substantially reduced cellular infiltration areas (Fig. 5E) . Our results clearly demonstrated that the iPSC-T regs were successful to reduce cartilage proteoglycan depletion and osteoclast-like activity (Fig. 5F ). Of note, in the OVA-injected knee, but not in the PBS treated-knees, reduced the cartilage depletion and osteoclast-like activity existed, suggesting that the iPSC-T regs are Ag-specific and functional, and Ag-specific iPSC-T regs are more efficient in suppressing the AIA than non Ag-specific T regs .
Collectively, these results demonstrate that Ag-specific iPSC-T regs are tissue-associated, and are able to migrate into local inflammation areas to prevent the joint damage in the AIA model.
In vivo persistence of Ag-specific iPSC-T regs .
The stability or plasticity of the T reg phenotype and function is a dynamic process modulated by inflammatory signals, T regs may down-regulate FoxP3 and lose regulatory activity 24 . We explored the in vivo persistence of Ag-specific iPSC-T regs . We co-cultured the OT-II TCR and + cells existed in the recipient mice, gated on live CD4 + population, which came from the transferred iPSC-derived cells, similar to the control OVA-specific nT regs from OT-II TCR transgenic (Tg) mice. In addition, these Thy 1.2 + cells highly expressed CD25 and FoxP3 (Fig. 6A ). This result indicated that the Ag-specific iPSC-T regs have a functional stability.
There is evidence that TCR has a key role in influencing the phenotype, function and localization of T regs in vivo 25, 26 . We analyzed the Ag specificity of OVA-specific iPSC-T regs by locating these cells in the OVA-treated knees. On day 14, after the AIA, we sacrificed mice and removed both knees for histopathological examination. Fluorescence microscopy revealed that more FoxP3
+ cells were present in the OVA-treated than PBS-treated knees; there was no FoxP3
+ cells existing in the knees in mice receiving the DsRed + vector-transduced iPSCs. Of note, much more CD4 + FoxP3 + TCRVβ 5 + cells presented in the knees in mice receiving iPSCs transduced with the MiDR-TCR-FoxP3 than MiDR-FoxP3 (Fig. 6B) . These data clearly suggest that the Ag-specific TCR and FoxP3 stably expressing in the iPSC-T regs drove them accumulating in the inflamed joints and efficiently suppressed the AIA.
Ag-specific iPSC-T regs ameliorate AIA by suppressing the development of IL-17 producing cells. To determine the mechanisms by which Ag-specific iPSC-T regs suppress the development of autoimmune arthritis, we investigated the role of IL-17 producing cells in the AIA model. IL-17 is a pro inflammatory cytokine produced mainly by activated T cells, and plays a pathogenic role in animal arthritis models and in human RA. Neutralizing IL-17 during the induction of collagen-induced arthritis (CIA) showed that IL-17 played a role in the early and late stages of the CIA. We monitored the number of Th17 producing cells in the AIA experiments. We adoptively transferred the iPSC-derived cells into the recipient mice before mBSA re-challenge. There were three groups of iPSC-derived cells: the MiDR vector, MiDR-FoxP3 15 , and MiDR-TCR-FoxP3. Compared to the MiDR and MiDR-FoxP3-treated mice, the MiDR-TCR-FoxP3-treated mice showed a significant reduction of Th17 producing cells (Fig. 6C ). There were similar numbers of Th17 producing cells in the PBS control knees (left), indicating that the suppression of Th17 numbers required the presence of the OVA Ag recognized by the iPSC-T regs . Of note, the ability to suppress the numbers of Th17 producing cells and swelling correlated with the ability to reduce joint inflammation, bone destruction, and osteoclast-like activity as judged by histopathology of tissue section. Taken together, these results suggested that Ag-specific iPSC-T regs ameliorate the development of AIA by suppressing Th17 producing cells and the suppressive activity is in an Ag dependent fashion.
Discussion
In this study, we show the generation of functional Ag-specific T regs by reprogramming iPSCs. In addition, we demonstrate that adoptive transfer of Ag-specific iPSC-T regs suppresses the development of AIA. Furthermore, we determine that Ag-specific iPSC-T regs ameliorate the development of AIA by suppressing Th17 producing cells and the suppressive activity is in an Ag dependent fashion. These results show that we develop a novel approach for developing potentially therapeutic Ag-specific T regs .
Strong arguments support the development of T reg -based therapies in autoimmune disorders using engineered T regs . While clinical trials show safety, feasibility, and potential therapeutic activity of T reg -based therapies using this approach, concerns about autoimmunity due to cross-reactivity with healthy tissues remains a major safety issue 27 . In addition, genetically modified T regs using current approaches are usually intermediate or later effector T regs that only have short-term persistence in vivo 28, 29 .
There are numerous advantages of T reg -based immunotherapy over conventional treatments. These benefits include: (1) the potential for Ag specificity with the lack of general immunosuppression; (2) the possibility of inducing long-lasting regulation in vivo, and (3) the custom-made product that can be designed for each patient, with very limited or absent side effects. However, due to the lack of T reg specific surface Ags, purification of a more comprehensive T reg subset increases the contamination by the non-regulatory T effs . Of note, in autoimmune prone mice or humans with autoimmune disorders, contamination of therapeutic T regs by non-regulatory T effs can include pathologic autoreactive lymphocytes. In addition, although naive T cells or thymocytes could be easily transduced with retrovirus containing FoxP3 [30] [31] [32] , the transfer of FoxP3 into the cells does not recapitulate the full repertoire of transcripts and functional characteristics of nT regs 33 . Furthermore, the generated T regs are not Ag-specific. Many examples exist that Ag-specific T regs are more effective in autoimmune syndromes when compared to polyclonal populations [34] [35] [36] . With this, a major challenge in Ag-specific T reg -based immunotherapy lies in the isolation of sufficient quantities of Ag-specific T cells -a challenge that is not easily overcome in humans where sampling is largely limited to the peripheral blood. A new approach by viral TCR gene transfer has been developed to generate Ag-specific T regs from a fully mature polyclonal nT regs population isolated from the peripheral blood mononuclear cells (PBMCs). This approach augmented the therapeutic profile of T regs in an arthritis murine model and redirected T regs in vivo 37 . However, TCR transduction of PBMCs will induce a T-cell population with mispaired TCRs, thereby reducing the surface density of Ag-specific TCR 38 . In contrast, transduction of stem cells followed by T cell lineage differentiation by in vitro or in vivo Notch signaling can overcome this problem 39, 40 .
To date, PSCs are the only source available to generate a high number of single-type Ag-specific T regs 15, 41, 42 . The approach to obtain embryonic stem cells (ESCs) from patients is not feasible. Hematopoietic stem cells (HSCs) have a higher potential to pass the bone marrow (BM) barrier and travel in the blood, which allows HSCs to be harvested from the patient blood following mobilization with hematopoietic growth factors. Thus, the use of HSCs for therapeutic purposes has been widely applied in the clinic, especially in HSC transplantations; however, HSCs are similar to other adult stem cells, which can proliferate only for a limited number of cycles. HSCs' response to differentiation signals decline with each cycle. In other words, compared to ESCs, HSCs have reduced differentiation and proliferative capacities, and the numbers of HSCs are difficult to expand + ) with AIA. Six weeks later, mice were sacrificed and the popliteal lymph nodes from the inflammatory right side were analyzed for CD4 + Thy 1.2 + cells. Data are representative of three independent experiments. The mean ± SD from three independent experiments is shown (*p < 0.05, one-way ANONA). (B) On days 7-14 after arthritis induction, the knees were removed and stained for immunohistology with CD4, FoxP3, and TCRVβ 5. Data are representative of five mice per group in three independent experiments. (C) On day 14 after arthritis induction, mice were sacrificed and the popliteal lymph nodes were removed from both sides, and the cells were analyzed for intracellular IL-17 staining, gating on CD4 + populations. Data are representative of three independent experiments. The mean ± SD from three independent experiments is shown (*p < 0.05, **p < 0.01, one-way ANOVA).
in cell culture 43 . Human iPSCs can be easily generated from patients' somatic cells by transduction of various transcription factors and exhibit characteristics identical to those of ESCs 44 . Many genetic methods as well as the protein-based approaches have been developed to produce iPSCs with potentially reduced risks, including that of immunogenicity and tumorigenicity 45 . This approach provides an opportunity to generate patient-or disease-specific iPSCs 46 . Because of the plasticity and the potential for an unlimited capacity for self-renewal, iPSCs have high potential for advancing the field of cell-based therapies. Our laboratory has shown that programming of Ag-specific iPSC-CTLs or iPSC-T regs can be used for immunotherapy of cancers and autoimmune disorders 15, 16, 42, 47 ; other groups reported related investigations 48, 49 . In this study, we have developed a system to generate Ag-specific iPSC-T regs . Our research provides a new insight into the methodologies and mechanistic requirements for efficient development of stable tissue-associated or organ-specific iPSC-T regs . Once such strategies become available, there is the potential to facilitate the generation of immune tolerance.
Although Ag-specific iPSC-T regs have promising therapeutic effects in cell-based therapies, their efficiency is limited by the need to generate a large number of such cells using complex and expensive in vitro differentiation. In addition, the lengthy duration for generating iPSCs may limit their use in individualized therapies. Alternatively, the TCR/FoxP3 gene-transduced iPSCs can be used to differentiate Ag-specific iPSC-T regs in vivo and suppress autoimmune disorders. After the adoptive transfer of the gene-transduced iPSCs, Notch agonists or recombinant cytokines (e.g., rIL-7, rFlt3L) can be administrated to boost in vivo development of Ag-specific iPSC-T regs . Another potential problem could arise including risks from the transferred cells potentially differentiating into other cell types (e.g., leukemia, lymphoma) in vivo or becoming dysfunctional. Alternatively, we will incorporate a suicide gene, the inducible caspase 9 59 , into the vector as this allows the removal of the transduced T regs by the injection of a bioinert small-molecule dimerizing agent (AP1903) to "shut off " the system, which will overcome this potential problem.
For autoimmune disorders like RA, it is unclear which Ags are critical for the disease. Clinical work has been performed targeting the autoAg that are relatively abundantly expressed in the inflamed synovium [50] [51] [52] . A clinical trial using heat shock protein (hsp) demonstrated clinical remission in patients with juvenile RA 53 . Recent studies have uncovered potent disease-suppressive T regs recognizing hsp self-Ags, enabling selective activity in inflamed tissues 8 . Generating hsp-specific iPSC-T regs for immunotherapy has a potential in the therapeutic interventions of autoimmune arthritis and lupus.
In summary, we have developed a new approach to generate functional Ag-specific iPSC-T regs , which have the ability to suppress autoimmunity in a murine model of arthritis. Targeting tissue/organ-associated iPSC-T regs may drive forward the use of therapeutic T regs of cell-based therapies. . OT-II TCR-Tg mice, expressing a TCR composed of variable (Vβ 5 and Vα 2) chains responsive to an OVA peptide 323-339 (ISQAVHAAHAEINEAGR), were bred on a C57BL/6 background. C57BL/6 (Thy1.2) and Thy1.1 congenic mice (B6.PL-Thy1a/Cy) mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Methods
Chemicals, peptide and antibodies. Albumin from chicken egg white (whole OVA, # 5503) and albumin methylated from bovine serum (mBSA, #A1009) were purchased from Sigma-Aldrich (St. Louis, MO). Complete Frenud's adjuvant (CFA, #263810) was purchased from BD Difco (Sparksm MD). OVA 323-339 peptide was purchased from the American Peptide Company (Sunnyvale, CA). PE or APC anti-mouse IL-2 (JES6-5H4) IFN-γ (XMG1.2) were obtained from BD Biosciences (San Diego, CA). PE, PE/Cy7, APC, APC/Cy7 or Alexa 647-conjugated anti-mouse CD4 (GK1.5), TCRVβ 5 (MR9-4), CD3 (17A2), CD25 (3C7), CTLA-4 (UC10-4B9), FoxP3 (MF-14), IL-10 (JES5-16E3), latency associated peptide/LAP (TGF-β 1, TW7-16B4), and Th17A (TC11-18H10.1) were obtained from Biolegend (San Diego, CA). Anti-FoxP3 Ab (ab54501) for immunofluorescent staining was purchased from Abcam (Cambridge, MA). Alexa Fluor 488-conjugated anti-mouse Nanog (eBioMLC-51) were obtained from eBioscoence (San Diego, CA). FITC-or PE-conjugated anti-mouse CD8 (6A242) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal anti-Cathepsin K Ab (#11239-1-AP) were purchased from Proteintech group (Chicago, IL). Mouse α -Notch2 Ab was kindly provided by Dr. Hideo Yagita (Juntendo University School of Medicine, Japan) 18 .
Cell cultures. Mouse iPSCs were maintained on feeder layers of irradiated SNL76/7 cells in 6-well culture plates (Nunc) and passaged every 3 days. In brief, iPSCs were maintained in DMEM culture medium Retroviral transduction. cDNA for FoxP3 or Foxp3 with OVA-specific TCR was subcloned into the murine bicistronic retroviral vector MSCV-IRES-DsRed (MiDR) 16 , and cloning was confirmed by PCR amplification and gene sequencing. Retroviral transduction was performed as described 15 .
Adoptive transfer. DsRed + T reg progenitors (3 × 10 6 ) from iPSCs in PBS were injected i.v. into 6-wk-old C57BL/6 mice. After 4-6 wk, mice were scarified, and the lymph nodes, spleen, or knees were removed for histopathological examination. Immunoblot. Live cells were lysed in ice-cold RIPA lysis buffer for 30 min. Insoluble material was removed and lysates were used for Western blotting as described 15 .
Flow cytometric analysis. Gene-transduced iPSCs (DsRed
Induction of Ag induced arthritis (AIA).
The gene-transduced iPSCs (DsRed + ) were co-cultured with OP9-DL1/DL4/I-A b cells for 7 days. The iPSC-derived cells were adoptively transferred to the female C57BL/6 mice through i.v. injection (day 0). At day 10, mice were s.c. immunized at the base of the tail with 100 μ g mBSA emulsified in complete Freund's adjuvant. At day 20, arthritis was induced by intra-articular injection of 20 μ g mBSA in 10 μ L PBS in the left knee and 20 μ g mBSA and 100 μ g whole OVA in 10 μ LPBS in the right knee. Arthritis severity was monitored by measurement of knee diameter using a dial gauge caliper from Kroeplin (Schluchtern, Germany). Increase in knee diameter was calculated based on pre-injection knee diameter for each mouse before injection on day 0 as described 9 .
Histology and immunofluorescence. Mice were sacrificed on day 7 after AIA induction. Both knees were removed, fixed in 10% formalin, and calcified in Formical-4 from Decal Chemical (Tallman, NY). The tissues were embedded in Paraffin, sectioned at 4 μ m, and stained with hematoxylin and eosin (HE) or Safranin O staining. Safranin O staining for bone erosion and loss of proteoglycans was scored using a semi quantitative scoring system from 0 to 4. For bone erosion, "0" is considered as no erosion, and "4" is considered as extended erosion and destruction of bone. For proteoglycans depletion, "0" represents no loss of proteoglycans, and "4" indicates a complete loss of staining for proteoglycans. HE staining for infiltration of inflammatory cells was scored using a semi quantitative scoring system as described 15 .
Immunofluorescent staining was performed on the sections after deparaffinization and rehydration as described 15 . Cathepsin K was diluted at 1:100 and incubated for 32 minutes followed by detection and visualization with Ventana Omnimap DAB anti-Rabbit detection kit.
Statistical analysis. One-way or two-way ANOVA was used for statistical analysis between groups and significance was set at 5%. All statistics were calculated using GraphPad Prism (San Diego, CA).
